Oxford Biomedica Share News (OXB)

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
Sanofi had given notice to "terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia", Oxford said on Friday.

"The group expects that the impact on revenue will be negligible over the coming 24 month period."